Screener
Krystal Biotech, Inc. KRYS Business Segments — Interest and other income, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended / March 31, 2026 | March 31, 2025 |
|---|---|---|
| Total research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Income from operations | $53,689 | $36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | $61,442 | $43,597 |
| Income tax expense | (5,510) | (7,864) |
| Net income | $55,932 | $35,733 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s business segments — interest and other income, net?
- Krystal Biotech, Inc. (KRYS) reported business segments — interest and other income, net of $7.75M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — interest and other income, net changed year-over-year?
- Krystal Biotech, Inc.'s business segments — interest and other income, net increased by 5.6% year-over-year, from $7.35M to $7.75M.
- What does business segments — interest and other income, net mean?
- Interest and other income, net, includes earnings from cash and investment balances, as well as miscellaneous non-operating gains or losses. This metric captures the financial returns generated by the company's treasury management and non-core activities.
Ask your AI about Krystal Biotech, Inc.'s business segments — interest and other income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude